반려동물 귀 감염증 치료 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the companion animal ear infection treatment market size is expected to increase from USD 0.77 billion in 2025 to USD 0.83 billion in 2026 and reach USD 1.25 billion by 2031, growing at a CAGR of 8.44% over 2026-2031.

This report is Segmented by Product Type [Antibacterial (Aminoglycosides and More), and More], Disease Type (Otitis Externa, and More), Animal Type (Dogs, and More), Mode of Administration (Topical, and More), Sales Channel (Veterinary Hospitals & Clinics, and More), Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Companion Animal Ear Infection Treatment Market Trends and Insights

Increasing Companion Animal Ownership Rates

Gen Z households drove a 43.5% jump in pet adoption between 2023 and 2024, lifting U.S. pet ownership to 94 million homes . Younger owners favor digital-first care, which funnels prescriptions toward e-commerce platforms integral to the companion animal ear infection treatment market. Urbanization in China and India reframes pets as family members, increasing per-capita spending on otic therapeutics. Breed predisposition among dogs with pendulous ears elevates infection incidence, ensuring recurring demand. Rural veterinary shortages affecting 129 million Americans further reinforce telehealth uptake that sustains prescription throughput

Rising Veterinary Healthcare Expenditure

Average annual outlays reached USD 598 for dogs and USD 529 for cats in 2025, but spending polarized: affluent owners embraced specialty services while cost-conscious segments deferred elective care . Ear infections remain non-deferrable, insulating revenue. GCC clinic openings and Brazil's expanding middle class replicate this pattern, though generic antibacterials dominate price-sensitive tiers.

Adverse Effects Associated with Long-Term Steroid Use

Chronic exposure to high-potency corticosteroids has been linked to iatrogenic Cushing-like syndromes, reported in 4.6% of canine otitis cases that required more than two refills of steroid-containing drops in 2025 pharmacovigilance data. These risks prompt dermatologists to reserve betamethasone or dexamethasone for acute flares and to pivot toward cytokine inhibitors such as oclacitinib or lokivetmab, which modulate specific interleukin pathways without broad immunosuppression. Insurers are beginning to impose step-therapy rules that require documentation of steroid intolerance before approving premium alternatives, slightly slowing uptake but reinforcing careful prescribing.

Over time, sustained safety scrutiny is expected to shift formulary preferences toward lower-dose combinations, probiotic adjuncts, and non-steroidal anti-inflammatories, constraining growth for legacy triple-combination drops within the companion animal ear infection treatment market.

Other drivers and restraints analyzed in the detailed report include:

1. Growing Availability of Advanced Otic Therapeutics
2. Expansion of Pet Telehealth Services
3. Low Owner Awareness of Early Ear Disease Symptoms

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Antibacterials captured 43.44% companion animal ear infection treatment market share in 2025, yet antifungals are set for a 9.11% CAGR on the back of rising Malassezia infections. The companion animal ear infection treatment market size for antifungals is projected to expand steadily as humid climates and floppy-eared breeds drive fungal prevalence. Combination gels blending florfenicol or marbofloxacin with terbinafine illustrate premium positioning, while corticosteroid-sparing formulas answer safety concerns.

Azole resistance remains uncommon, giving antifungals headroom, whereas stewardship guidelines diminish empirical fluoroquinolone use. Blue-light phototherapy trials posted pathogen-load reductions without antimicrobials. Microbiome products remain experimental, but investor interest signals potential long-term disruption to the companion animal ear infection treatment industry.

Otitis externa generated 65.12% of 2025 revenue, confirming its dominance within the companion animal ear infection treatment market. Yet otitis interna is pacing a 9.25% CAGR because referral centers now deploy CT and MRI to detect inner-ear disease earlier. The companion animal ear infection treatment market size attached to advanced imaging referrals is growing as vestibular signs trigger specialist evaluation.

Severe externa splits into mild and chronic cohorts: the first group favors low-cost generics, the second opts for compliance-independent long-acting gels. Otitis media often involves surgical myringotomy, concentrating revenue in specialty hospitals.

Complete Report Scope:

• By Product Type
  • Antibacterial
    • Aminoglycosides
    • Fluoroquinolones
    • Other Antibacterial Products
  • Antifungal
  • Corticosteroids
  • Other Product Types
• By Disease Type
  • Otitis Externa
  • Otitis Media
  • Otitis Interna
• By Animal Type
  • Dogs
  • Cats
  • Other Animal Types
• By Mode of Administration
  • Topical
  • Oral
  • Otic
• By Sales Channel
  • Veterinary Hospitals & Clinics
  • Retail Pharmacies & Pet Stores
  • Online Pharmacies & Direct-to-Consumer
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America generated 43.43% of global revenue in 2025, underpinned by high insurance penetration, strong clinic density, and premium pricing levels. The companion animal ear infection treatment market size in the region remains resilient despite macro headwinds because ear infections are non-elective. Stewardship guidelines reduce fluoroquinolone volume but lift demand for culture tests and narrow agents. Rural shortages drive telehealth uptake, coupling virtual care with mail-order delivery to maintain access.

Europe follows with a mature framework characterized by stringent antimicrobial stewardship and 25%-plus insurance coverage in core markets. Harmonized EMA approvals expedite cross-border launches, yet differences in compounding rules still fragment distribution. Market growth is steady but slower than Asia-Pacific due to already high baseline penetration.

Asia-Pacific posts the fastest 9.77% CAGR, propelled by China and India, where rising disposable incomes and shifting cultural values elevate pets to family status. E-commerce channels dominate urban centers, letting manufacturers sidestep uneven clinic networks. Local production partnerships, such as Vetoquinol's 2025 joint venture in China, accelerate regulatory navigation and cut logistics costs.

South America shows a bifurcated profile: Brazil's middle class expands demand, but price sensitivity keeps generics dominant. GCC states invest in new clinics, yet warm climates raise cold-chain challenges for biologics. Africa remains nascent with limited data, but urban middle classes in South Africa and Kenya show early adoption of premium pet care. Collectively, emerging markets diversify revenue streams and cushion saturation risks in established regions of the companion animal ear infection treatment market.

1. Bimeda Animal Health
2. Boehringer Ingelheim
3. Ceva Sante Animale
4. Chanelle Pharma
5. Dechra Pharmaceuticals
6. Elanco Animal Health Inc.
7. Innovet Italia
8. Med-Pharmex
9. Merck
10. Nexvet Biopharma
11. Norbrook Laboratories
12. Vetoquinol
13. Virbac
14. Zoetis
15. Zymox

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Increasing Companion Animal Ownership Rates
  • 4.2.2 Rising Veterinary Healthcare Expenditure
  • 4.2.3 Growing Availability of Advanced Otic Therapeutics
  • 4.2.4 Expansion of Pet Telehealth Services
  • 4.2.5 Emerging Microbiome-Based Treatment Approaches
  • 4.2.6 Proactive Wellness Programs by Pet Insurers
• 4.3 Market Restraints
  • 4.3.1 Adverse Effects Associated with Long-Term Steroid Use
  • 4.3.2 Low Owner Awareness of Early Ear Disease Symptoms
  • 4.3.3 Escalating Antimicrobial Resistance in Otic Pathogens
  • 4.3.4 Regulatory Restrictions on Compounded Otic Formulations
• 4.4 Regulatory Landscape
• 4.5 Porter's Five Forces
  • 4.5.1 Threat of New Entrants
  • 4.5.2 Bargaining Power of Buyers/Consumers
  • 4.5.3 Bargaining Power of Suppliers
  • 4.5.4 Threat of Substitute Products
  • 4.5.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product Type
  • 5.1.1 Antibacterial
    • 5.1.1.1 Aminoglycosides
    • 5.1.1.2 Fluoroquinolones
    • 5.1.1.3 Other Antibacterial Products
  • 5.1.2 Antifungal
  • 5.1.3 Corticosteroids
  • 5.1.4 Other Product Types
• 5.2 By Disease Type
  • 5.2.1 Otitis Externa
  • 5.2.2 Otitis Media
  • 5.2.3 Otitis Interna
• 5.3 By Animal Type
  • 5.3.1 Dogs
  • 5.3.2 Cats
  • 5.3.3 Other Animal Types
• 5.4 By Mode of Administration
  • 5.4.1 Topical
  • 5.4.2 Oral
  • 5.4.3 Otic
• 5.5 By Sales Channel
  • 5.5.1 Veterinary Hospitals & Clinics
  • 5.5.2 Retail Pharmacies & Pet Stores
  • 5.5.3 Online Pharmacies & Direct-to-Consumer
• 5.6 By Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 India
    • 5.6.3.3 Japan
    • 5.6.3.4 South Korea
    • 5.6.3.5 Australia
    • 5.6.3.6 Rest of Asia-Pacific
  • 5.6.4 Middle East and Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East and Africa
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Bimeda Animal Health
  • 6.3.2 Boehringer Ingelheim Animal Health
  • 6.3.3 Ceva Sante Animale
  • 6.3.4 Chanelle Pharma
  • 6.3.5 Dechra Pharmaceuticals PLC
  • 6.3.6 Elanco Animal Health Inc.
  • 6.3.7 Innovet Italia
  • 6.3.8 Med-Pharmex
  • 6.3.9 Merck & Co., Inc.
  • 6.3.10 Nexvet Biopharma
  • 6.3.11 Norbrook Laboratories
  • 6.3.12 Vetoquinol SA
  • 6.3.13 Virbac SA
  • 6.3.14 Zoetis Inc.
  • 6.3.15 Zymox

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment